Humacyte (HUMA) Cash & Equivalents (2020 - 2026)
Humacyte (HUMA) posted quarterly Cash & Equivalents of $48.5 million for Q1 2026, down 22.77% year-over-year from $62.8 million in Q1 2025, and down 3.88% quarter-over-quarter from $50.5 million in Q4 2025.
Humacyte (HUMA) Cash & Equivalents (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Cash & Equivalents for 7 consecutive years, with $48.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents fell 22.77% year-over-year to $48.5 million; the TTM figure through Mar 2026 stood at $48.5 million (down 22.77% YoY), while the FY2025 annual figure was $50.5 million, up 12.37% from the prior year.
- Cash & Equivalents eased to $48.5 million in Q1 2026 per HUMA's latest filing, from $50.5 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $198.2 million in Q1 2022 and bottomed at $19.5 million in Q3 2025.
- Historically, Cash & Equivalents has averaged $94.8 million across 5 years, with a median of $93.6 million in 2024.
- Annual changes were most pronounced in 2022 — Cash & Equivalents surged 47118.31% — and 2024, when it tumbled 79.43%.
- Humacyte's Cash & Equivalents stood at $149.8 million in 2022, then tumbled by 46.29% to $80.4 million in 2023, then plunged by 44.14% to $44.9 million in 2024, then gained by 12.37% to $50.5 million in 2025, then declined by 3.88% to $48.5 million in 2026.
- Business Quant data shows HUMA's Cash & Equivalents at $48.5 million in Q1 2026, $50.5 million in Q4 2025, and $19.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 | 79.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.90 Mn |
| Mar 31, 2026 | 48.54 Mn |
| Dec 31, 2025 | 50.50 Mn |
| Sep 30, 2025 | 19.49 Mn |
| Jun 30, 2025 | 38.00 Mn |
| Mar 31, 2025 | 62.85 Mn |
| Dec 31, 2024 | 44.94 Mn |
| Sep 30, 2024 | 20.57 Mn |
| Jun 30, 2024 | 93.56 Mn |
| Mar 31, 2024 | 115.50 Mn |
| Dec 31, 2023 | 80.45 Mn |
| Sep 30, 2023 | 100.00 Mn |
| Jun 30, 2023 | 114.60 Mn |
| Mar 31, 2023 | 129.57 Mn |
| Dec 31, 2022 | 149.77 Mn |
| Sep 30, 2022 | 163.73 Mn |
| Jun 30, 2022 | 181.04 Mn |
| Mar 31, 2022 | 198.22 Mn |
| Dec 31, 2021 | 217.50 Mn |
| Sep 30, 2021 | 240.40 Mn |